<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37384409</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>16</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e138207</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI138207</ELocationID><Abstract><AbstractText>Protein aggregation is a hallmark of many neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Although mutations in TARDBP, encoding transactive response DNA-binding protein 43 kDa (TDP-43), account for less than 1% of all ALS cases, TDP-43-positive aggregates are present in nearly all ALS patients, including patients with sporadic ALS (sALS) or carrying other familial ALS-causing (fALS-causing) mutations. Interestingly, TDP-43 inclusions are also present in subsets of patients with frontotemporal dementia, Alzheimer's disease, and Parkinson's disease; therefore, methods of activating intracellular protein quality control machinery capable of clearing toxic cytoplasmic TDP-43 species may alleviate disease-related phenotypes. Here, we identify a function of nemo-like kinase (Nlk) as a negative regulator of lysosome biogenesis. Genetic or pharmacological reduction of Nlk increased lysosome formation and improved clearance of aggregated TDP-43. Furthermore, Nlk reduction ameliorated pathological, behavioral, and life span deficits in 2 distinct mouse models of TDP-43 proteinopathy. Because many toxic proteins can be cleared through the autophagy/lysosome pathway, targeted reduction of Nlk represents a potential approach to therapy development for multiple neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tejwani</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Youngseob</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokubu</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sowmithra</LastName><ForeName>Sowmithra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Luhan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Changwoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Yangfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luttik</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Armand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yale College, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Junhyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ro</LastName><ForeName>Hannah H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Yale College, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Hyoungseok</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tieze</LastName><ForeName>Sofia Massaro</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paymaan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Janghoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdepartmental Neuroscience Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration and Repair, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Stem Cell Center, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 MH119803</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS083706</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG076154</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066447</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG074609</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007224</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C470551">NLK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C408347">Nlk protein, mouse</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Lysosomes</Keyword><Keyword MajorTopicYN="N">Mouse models</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>12</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37384409</ArticleId><ArticleId IdType="pmc">PMC10425213</ArticleId><ArticleId IdType="doi">10.1172/JCI138207</ArticleId><ArticleId IdType="pii">138207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, et al. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61(5):435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221&#x2013;229. doi: 10.1007/s00401-007-0261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju H, et al. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1. J Neurosci. 2013;33(22):9328&#x2013;9336. doi: 10.1523/JNEUROSCI.3465-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3465-12.2013</ArticleId><ArticleId IdType="pmc">PMC3710458</ArticleId><ArticleId IdType="pubmed">23719801</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd TW, et al. Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy. Elife. 2015;4:e08493. doi: 10.7554/eLife.08493.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.08493</ArticleId><ArticleId IdType="pmc">PMC4577982</ArticleId><ArticleId IdType="pubmed">26308581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, et al. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington&#x2019;s disease. Hum Mol Genet. 2020;29(8):1340&#x2013;1352. doi: 10.1093/hmg/ddaa061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa061</ArticleId><ArticleId IdType="pmc">PMC7254850</ArticleId><ArticleId IdType="pubmed">32242231</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SZ, et al. Nemo-like kinase (NLK) negatively regulates NF-kappa B activity through disrupting the interaction of TAK1 with IKK&#x3b2;. Biochim Biophys Acta. 2014;1843(7):1365&#x2013;1372. doi: 10.1016/j.bbamcr.2014.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2014.03.028</ArticleId><ArticleId IdType="pmc">PMC4655877</ArticleId><ArticleId IdType="pubmed">24721172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380&#x2013;1389. doi: 10.1016/j.cell.2013.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.08.021</ArticleId><ArticleId IdType="pmc">PMC3856256</ArticleId><ArticleId IdType="pubmed">23992846</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33(12):5352&#x2013;5361. doi: 10.1523/JNEUROSCI.6103-11.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6103-11.2013</ArticleId><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci. 2014;17(9):1180&#x2013;1189. doi: 10.1038/nn.3787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3787</ArticleId><ArticleId IdType="pmc">PMC4180729</ArticleId><ArticleId IdType="pubmed">25108912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473&#x2013;477. doi: 10.1126/science.1174447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1174447</ArticleId><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429&#x2013;1433. doi: 10.1126/science.1204592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1204592</ArticleId><ArticleId IdType="pmc">PMC3638014</ArticleId><ArticleId IdType="pubmed">21617040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, et al. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3(5):452&#x2013;460. doi: 10.4161/auto.4451.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.4451</ArticleId><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano G, Ballabio A. TFEB at a glance. J Cell Sci. 2016;129(13):2475&#x2013;2481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958300</ArticleId><ArticleId IdType="pubmed">27252382</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31(5):1095&#x2013;1108. doi: 10.1038/emboj.2012.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.32</ArticleId><ArticleId IdType="pmc">PMC3298007</ArticleId><ArticleId IdType="pubmed">22343943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78(5):761&#x2013;771. doi: 10.1016/S0092-8674(94)90462-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(94)90462-6</ArticleId><ArticleId IdType="pubmed">8087844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, et al. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol. 2000;18(5):538&#x2013;543. doi: 10.1038/75406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75406</ArticleId><ArticleId IdType="pubmed">10802622</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol. 2016;18(10):1065&#x2013;1077. doi: 10.1038/ncb3407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3407</ArticleId><ArticleId IdType="pubmed">27617930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega-Rubin-de-Celis S, et al. Multistep regulation of TFEB by MTORC1. Autophagy. 2017;13(3):464&#x2013;472. doi: 10.1080/15548627.2016.1271514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1271514</ArticleId><ArticleId IdType="pmc">PMC5361595</ArticleId><ArticleId IdType="pubmed">28055300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Llopis S, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011;30(16):3242&#x2013;3258. doi: 10.1038/emboj.2011.257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.257</ArticleId><ArticleId IdType="pmc">PMC3160667</ArticleId><ArticleId IdType="pubmed">21804531</ArticleId></ArticleIdList></Reference><Reference><Citation>Roczniak-Ferguson A, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42. doi: 10.1126/scisignal.2002790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2002790</ArticleId><ArticleId IdType="pmc">PMC3437338</ArticleId><ArticleId IdType="pubmed">22692423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, et al. Role of autophagy in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2015;1852(11):2517&#x2013;2524. doi: 10.1016/j.bbadis.2015.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.08.005</ArticleId><ArticleId IdType="pubmed">26264610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, et al. Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis. Elife. 2019;8:e40811. doi: 10.7554/eLife.40811.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.40811</ArticleId><ArticleId IdType="pmc">PMC6389288</ArticleId><ArticleId IdType="pubmed">30747709</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res. 2010;88(4):784&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19798749</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 2014;127(pt 6):1263&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10(8):677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A. 2012;109(37):15024&#x2013;15029. doi: 10.1073/pnas.1206362109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63(4):535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J Clin Invest. 2020;130(3):1139&#x2013;1155. doi: 10.1172/JCI130988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106(44):18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59&#x2013;72. doi: 10.1016/j.brainres.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.10.013</ArticleId><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J Neurochem. 2005;93(4):875&#x2013;882. doi: 10.1111/j.1471-4159.2005.03054.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03054.x</ArticleId><ArticleId IdType="pubmed">15857390</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9&#x2013;21. doi: 10.1038/nrneurol.2017.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.148</ArticleId><ArticleId IdType="pubmed">29192260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7(3):774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017&#x2013;3026. doi: 10.1016/S0140-6736(16)31408-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31408-8</ArticleId><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, et al. Targeting huntingtin expression in patients with Huntington&#x2019;s disease. N Engl J Med. 2019;380(24):2307&#x2013;2316. doi: 10.1056/NEJMoa1900907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1900907</ArticleId><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107(8):3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet SJ, et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp. 2010;(39):1787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, et al. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. Dis Model Mech. 2016;9(9):1029&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, et al. Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation. Neurosci Lett. 2010;465(7295):223&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">22040667</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C, et al. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum Mol Genet. 2018;27(9):1593&#x2013;1607. doi: 10.1093/hmg/ddy066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy066</ArticleId><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031&#x2013;1044. doi: 10.1016/j.neuron.2012.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.05.009</ArticleId><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich J, et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight. 2018;3(21):123193. doi: 10.1172/jci.insight.123193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123193</ArticleId><ArticleId IdType="pmc">PMC6238731</ArticleId><ArticleId IdType="pubmed">30385727</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544(7650):362&#x2013;366. doi: 10.1038/nature22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22044</ArticleId><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong T, et al. Microglia regulate brain progranulin levels through the endocytosis/lysosomal pathway. JCI Insight. 2021;6(22):136147. doi: 10.1172/jci.insight.136147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.136147</ArticleId><ArticleId IdType="pmc">PMC8663778</ArticleId><ArticleId IdType="pubmed">34618685</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas CA, et al. Modeling of TREX1-dependent autoimmune disease using human stem cells highlights L1 accumulation as a source of neuroinflammation. Cell Stem Cell. 2017;21(3):319&#x2013;331. doi: 10.1016/j.stem.2017.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2017.07.009</ArticleId><ArticleId IdType="pmc">PMC5591075</ArticleId><ArticleId IdType="pubmed">28803918</ArticleId></ArticleIdList></Reference><Reference><Citation>Du ZW, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6:6626. doi: 10.1038/ncomms7626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7626</ArticleId><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36. doi: 10.1186/gb-2013-14-4-r36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2013-14-4-r36</ArticleId><ArticleId IdType="pmc">PMC4053844</ArticleId><ArticleId IdType="pubmed">23618408</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A, et al. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 2011;12(3):R22. doi: 10.1186/gb-2011-12-3-r22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-3-r22</ArticleId><ArticleId IdType="pmc">PMC3129672</ArticleId><ArticleId IdType="pubmed">21410973</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511&#x2013;515. doi: 10.1038/nbt.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1621</ArticleId><ArticleId IdType="pmc">PMC3146043</ArticleId><ArticleId IdType="pubmed">20436464</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562&#x2013;578. doi: 10.1038/nprot.2012.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.016</ArticleId><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267&#x2013;273. doi: 10.1038/ng1180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1180</ArticleId><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaimal V, et al. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res. 2010;38(web server issue):W96&#x2013;W102. doi: 10.1093/nar/gkq418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq418</ArticleId><ArticleId IdType="pmc">PMC2896202</ArticleId><ArticleId IdType="pubmed">20484371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology consortium. Nat Genet. 2000;25(1):25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Consortium. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 2019;47(d1):D330&#x2013;D338. doi: 10.1093/nar/gky1055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1055</ArticleId><ArticleId IdType="pmc">PMC6323945</ArticleId><ArticleId IdType="pubmed">30395331</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner M, et al. Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents. J Vis Exp. 2017;(119):55226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5352284</ArticleId><ArticleId IdType="pubmed">28190031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Swayze EE, et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 2007;35(2):687&#x2013;700. doi: 10.1093/nar/gkl1071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl1071</ArticleId><ArticleId IdType="pmc">PMC1802611</ArticleId><ArticleId IdType="pubmed">17182632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>